Search results
Results from the WOW.Com Content Network
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. [6] Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.
Filgrastim is a recombinant form of the naturally occurring granulocyte colony-stimulating factor (G-CSF). [21] It works by stimulating the body to increase neutrophil production. [21] Filgrastim was approved for medical use in the United States in 1991. [21] It is on the World Health Organization's List of Essential Medicines.
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. [19] It serves to stimulate the production of white blood cells (neutrophils). [19] [21] Pegfilgrastim was developed by Amgen. [22]
A tenth, approved in November, is predicted to run about $3.8 million, just shy of the most expensive, also approved last year, which costs $4.25 million a dose. “Drug companies charge whatever ...
A 2014 Canadian study calculated the cost per life-year-gained with treatment as CAN$4.62 million (US$4,571,564) and cost per quality-adjusted-life-year as CAN$2.13 million (US$2,112,398)."The incremental cost per life year and per QALY gained is CAN$4.62 million and CAN$2.13 million, respectively.
It could also cost $550 a month for people with health insurance that doesn’t cover the drug. Unfortunately, Medicare and Medicaid don’t cover weight loss medications like Zepbound, Dr. Shah says.
Following the listing of the combination on the Pharmaceutical Benefits Scheme in 2022, the cost for people aged twelve years of age or older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene is $30.00 per month, or $7.30 for concession card holders. [48]
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2]